January/February 2011

home / publications / ajpb / ajpb_11jan
Site Logo

2010 Drug Utilization and Cost Trends for Antidiabetic Agents

Anna A. Theodorou, RPh, MBA;Kelly M. Johnson, MBA;Mark W. Ward, BA;John A. Szychowski, AAS, BS
February 4th 2011
ArticleThe American Journal of Pharmacy Benefits

The antihyperglycemic therapeutic class will continue to be a major contributor to prescription drug trends in 2011 and beyond.

Site Logo

Impact of Generic Drug Discount Programs on Managed Care Organizations

Harshali K. Patel, MS;Nilanjana Dwibedi, MBA, MS;Anthony Omojasola, DrPH;Sujit S. Sansgiry, MS, PhD
February 3rd 2011
ArticleThe American Journal of Pharmacy Benefits

Generic drug discount programs, which differ across large chain pharmacies, may result in significant savings for managed care organizations.

Site Logo

Evaluation of Therapeutic Interchange From Donepezil to Galantamine Extended-Release

Sophia Pak, PharmD;Mark Bounthavong, PharmD;Melissa L. Christopher, PharmD;Margaret A. Mendes, PharmD;Emerald B. Foster, PharmD;Daniel T. Boggie, PharmD;Jonathan Lacro, PharmD, BCPS, BCPP;a
February 2nd 2011
ArticleThe American Journal of Pharmacy Benefits

Therapeutic interchange from donepezil to galantamine extended-release: a 3-month analysis.

Site Logo

Diabetes Quality Measurement: A Primer for Pharmacists

Laura T. Pizzi, PharmD, MPH, RPh;Dante A. Gravino, PharmD Candidate;Kangho Suh, PharmD Candidate
February 2nd 2011
ArticleThe American Journal of Pharmacy Benefits

The continuing education article reviews diabetes quality improvement efforts and the potential for expanding the role of pharmacists as clinical care providers.

Site Logo

Costs Associated With Second-Line Therapies for Lung Cancer

Stephen Lash, PharmD;April Teitelbaum, MD;Henry J. Henk, PhD;Carolina M. Reyes, PhD;Lucinda Benn, MBA
February 2nd 2011
ArticleThe American Journal of Pharmacy Benefits

Erlotinib may confer an economic advantage for payers over docetaxel and pemetrexed for second-line treatment of lung cancer because of lower costs.

Site Logo

Utility of the PhaSeal Closed System Drug Transfer Device

Derek M. McMichael, PharmD;Dawn Moore Jefferson, PharmD;E. Thomas Carey, PharmD;Ryan A. Forrey, PharmD, MS;Susan M. Spivey, PharmD, DDS;John M. Mulvaney, MHA;James A. Jorgenson, RPh, MS;R.
February 2nd 2011
ArticleThe American Journal of Pharmacy Benefits

The Phaseal closed system drug transfer device provides a mechanical barrier to the entry of contaminants into sterile solutions for up to 168 hours.

Site Logo

The New World of Neurology

Jan E. Berger, MD, MJ—Editor-in-Chief
February 2nd 2011
ArticleThe American Journal of Pharmacy Benefits

The large number of medications to treat neurologic conditions that are in the pipeline will require assessment of safety, efficacy, and cost-effectiveness.